Table search / Registration and prospectus / Quoin Pharmaceuticals, Ltd.

The as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined at pricing. You should read the information in this table together with our audited financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 , incorporated by reference in this prospectus.

After giving effect to the sale by us in this offering of 19,230,769 ADSs at a price of $0.78 per ADS and accompanying Warrants, based on the closing price of our ADSs on Nasdaq on December 9, 2024, after deducting the Placement Agent fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants in this offering and no exercise of any Warrants, our as adjusted net tangible book value as of September 30, 2024, would have been approximately $18.3 million, or approximately $0.75 per ADS. This represents an immediate decrease in net tangible book value of approximately $0.23 per ADS to our existing security holders and an immediate dilution in as adjusted net tangible book value of approximately $0.03 per ADS to purchasers of ADSs in this offering. The final public offering price will be determined through negotiation between us, the Placement Agent, and prospective investors in the offering and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. The following table illustrates this per share dilution:

The following table sets forth the various costs and expenses, other than the placement agent’s fees and expenses, to be paid in connection with the offering of securities described in this registration statement. All the amounts shown are estimates except the SEC registration fee.

After giving effect to the sale by us in this offering of 19,230,769 ADSs at a price of $0.78 per ADS and accompanying Warrants, based on the closing price of our ADSs on Nasdaq on December 9, 2024, after deducting the Placement Agent fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants in this offering and no exercise of any Warrants, our as adjusted net tangible book value as of September 30, 2024, would have been approximately $18.3 million, or approximately $0.75 per ADS. This represents an immediate decrease in net tangible book value of approximately $0.23 per ADS to our existing security holders and an immediate dilution in as adjusted net tangible book value of approximately $0.03 per ADS to purchasers of ADSs in this offering. The final public offering price will be determined through negotiation between us, the Placement Agent, and prospective investors in the offering and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. The following table illustrates this per share dilution:

The following table sets forth the various costs and expenses, other than the placement agent’s fees and expenses, to be paid in connection with the offering of securities described in this registration statement. All the amounts shown are estimates except the SEC registration fee.